Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure checklist aims to boost lifesaving drug use

NCT ID NCT06847438

Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether giving heart failure patients a one-page checklist of recommended medications helps doctors prescribe them more often. The checklist lists guideline-approved drugs and doses for heart failure with reduced ejection fraction. Researchers will enroll 4000 patients across cardiology clinics to see if this simple tool increases use of these lifesaving medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EPIC-HF checklist (a one-page patient activation tool listing recommended heart failure medications)
What this could lead to
If this works, it could help more heart failure patients get the right medications, potentially improving their health and reducing hospital visits.
What could go wrong
This is a large but early-stage behavioral study, not testing a new drug. The checklist may not change prescribing habits as hoped, and results may vary across clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3,966 people

The number who actually took part.

Started

Mar 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ejection fraction (EF) less than or equal to 40% by echocardiogram performed in the prior 18 months * Diagnosis of heart failure Exclusion Criteria: * Heart failure (HF) etiology for which GDMT is not indicated: including hypertrophic or restrictive cardiomyopathy (e.g. amyloid cardiomyopathy), constrictive pericarditis, or complex congenital heart disease * End-stage HF requiring continuous inotrope infusion, heart transplant, or left ventricular assist device * Estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m\^2 * Any conditions other than HF that are likely to alter the patient's status over 6 months, indicated by active hospice status

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Emory Johns Creek Hospital

    Johns Creek, Georgia, 30097, United States

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia, 30308, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.